menu
    • menu
    [{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hillstream BioPharma Presentations at 2020 AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Salinomycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$2.6 million","upfrontCash":"Undisclosed","newsHeadline":"Hillstream BioPharma Announces Closing of Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"Salinomycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ ThinkEquity","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ ThinkEquity"}]

    Find Clinical Drug Pipeline Developments & Deals for Salinomycin

    Menu

    Salinomycin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hillstream BioPharma

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Hillstream BioPharma

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salinomycin

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : ThinkEquity

                            Deal Size : $2.6 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Hillstream BioPharma Announces Closing of Public Offering of Common Stock

                            Details : The Company intends to use the net proceeds for the advancement of its lead drug candidate HSB-1216, which targets ferroptosis, an emerging new anti-cancer mechanism, and the development of other product candidates in the Company’s pipeline.

                            Brand Name : HSB-1216

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 02, 2023

                            Lead Product(s) : Salinomycin

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : ThinkEquity

                            Deal Size : $2.6 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hillstream BioPharma

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Hillstream BioPharma

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salinomycin

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Hillstream BioPharma Presentations at 2020 AACR Virtual Annual Meeting II

                            Details : Abstracts highlight data from HSB-1216 (Salinomycin QUATRAMER™) in small cell lung cancer and triple negative breast cancer.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 19, 2020

                            Lead Product(s) : Salinomycin

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth